OptiScan Imaging Limited (ASX: OIL (‘the Company’ or‘OptiScan’), has been awarded a grant of almost $1 million by the Australian Government, which will help fund a trial to improve screening, diagnosis and treatment of oral cancer.
The BioMedTech Horizons Program is an initiative of the Medical Research Future Fund, operated by MTPConnect. It is designed to foster innovative collaborative health technology development, and stimulate collaboration across disciplines and between the research, industry, and technology sectors to maximise entrepreneurship and idea potential.
The Program’s latest round of funding, was open to medical device projects targeting innovative solutions to address unmet clinical needs in three key focus areas, including general medical devices in oncology.
To read the full ASX announcement, click here.
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early-stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.